scholarly journals The Effect of Bone Marrow Transplantation on Oocyte-Granulosa Cell Interaction and Follicular Development of Cisplatin-Induced Ovarian Failure in Rat

2020 ◽  
Vol 4 (2) ◽  
pp. 56
Author(s):  
Hendi Hendarto
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Granulosa Cell ◽  
Marrow Transplantation ◽  
Follicular Development ◽  
Cell Interaction ◽  
Ovarian Failure ◽  
Control Group ◽  
Kit Ligand ◽  
Development Evaluation

Introduction: Chemotherapy has cytotoxic effect that induces follicular damage and abnormal folliculogenesis leads to ovarian failure. Two crucial   growth factors in abnormal folliculogenesis, Growth Differentiation Factor-9 (GDF-9) and Kit-Ligand, will be disrupted and affect follicular development. In this study, we evaluate whether bone marrow transplantation (BMT) has a role on oocyte-granulosa cell interaction by analyzing GDF-9 and Kit-Ligand expressions and also follicular development by analyzing primordial, primary, secondary and graafian follicles of cisplatin-induced ovarian failure in rat. Material and method: Forty eight rats were divided into three groups: control, cisplatin and cisplatin + BMT. Ovarian failure was induced by administration   of intraperitoneal cisplatin 5 mg/kg body weight for 1 week. BMT 2 x107 cells were injected through rat tail vein after cisplatin administration.  Bone marrow was isolated from rat femur and characterized    by CD44(+), CD45(-), CD105(+). Immunohistochemistry examinations for ovarian GDF-9, Kit-Ligand and follicle development evaluation were performed after 2 weeks of BMT injection. Results:  The  expressions   of Kit-ligand  among  three  groups  by ANOVA were  significant different (p=0.00), whereas by Post Hoc: cisplatin group lower  than  control  group (p=0.00); cisplatin + BMT group  higher than  cisplatin group (p=0.00); and no significant different between  control  group and cisplatin + BMT group (p=0.955). The expressions of GDF-9 by Kruskal Wallis showed significant different (p=0.00) among three groups whereas cisplatin + BMT group higher than cisplatin group and control group. In cisplatin + BMT group the number of primordial, primary, secondary and graafian follicles were higher than those in cisplatin group; but were lower than those in control group (p=0.000). Positive Paul Kart Horan (PKH) labeling was seen in cisplatin + BMT   group only. Conclusion:  In cisplatin-induced ovarian failure in rat, bone marrow transplantation may improve oocytegranulosa cell interaction and follicular development.

Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation.

1989 ◽  
Vol 7 (11) ◽  
pp. 1685-1692 ◽  
Author(s):  
J Neidhart ◽  
A Mangalik ◽  
W Kohler ◽  
C Stidley ◽  
J Saiki ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Supportive Therapy ◽  
Control Group ◽  
Hematologic Toxicity ◽  
Intensive Chemotherapy ◽  
Duration Of Hospitalization ◽  
Effective Doses ◽  
Stimulating Factor

Bone marrow colony-stimulating factors (CSF) ameliorate hematologic toxicity of standard chemotherapy regimens and may allow relatively safe use of intensive and more efficacious doses of anticancer drugs. Twenty-four patients with cancers for which no standard regimens were likely to be effective received repeated courses of a combination of cisplatin (150 mg/m2), etoposide (1,500 mg/m2), and cyclophosphamide (5,000 mg/m2) at doses for which bone marrow transplantation is usually used. A total of 10 patients received escalating doses of recombinant human granulocyte CSF (rhG-CSF); 11 patients receiving identical chemotherapy and supportive therapy without rhG-CSF served as controls for the first cycle of therapy. Five of these patients and 3 additional patients also served as their own controls, receiving rhG-CSF for all cycles after the first. No patient received bone marrow transplantation. rhG-CSF shortened the median duration of severe granulocytopenia (less than or equal to 100/mm3) in a dose-related fashion (P less than .03; Kruskal-Wallis test). Patients not receiving rhG-CSF had a median of 8.5 days of granulocytopenia. Those receiving 40 micrograms/kg of rhG-CSF for approximately 20 days from the third day after chemotherapy had a median of 7.0 days (P less than .23) and those receiving 60 micrograms/kg had a median of 5.5 days (P less than .007) of granulocytopenia. An rhG-CSF dose of 20 micrograms/kg had no effect. Recovery to a granulocyte count of at least 500/mm3 took a median of 12 days in the control group and 8 days (P less than .03) in patients receiving rhG-CSF at a dose of 60 mg/kg. The duration of antibiotic therapy (a median, 9.0 days v 5.0 days) was shortened with the two higher and effective doses of rhG-CSF compared with control patients. The duration of hospitalization (median of 20 days v 19 days) was not shortened. These findings that rhG-CSF decreases the risk of granulocytopenia associated with this particular dose-intensive chemotherapy regimen therapy administered without bone marrow transplantation.

Unexpected 5 Year Survival Benefit in Patients Given Oral Cryotherapy During Conditioning for Stem Cell Transplantation. A Prospective Randomized Study

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4559-4559
Author(s):  
Anncarin Svanberg ◽  
Kerstin Öhrn ◽  
Gunnar Birgegard
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Bone Marrow Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Marrow Transplantation ◽  
High Dose Chemotherapy ◽  
Control Group ◽  
High Dose ◽  
Oral Cryotherapy

Abstract Abstract 4559 Patients receiving high dose chemotherapy (HDC) in connection with bone marrow transplantation (BMT) often are afflicted with severe oral mucositis (OM). OM may affect 75–99% of patients. Oral cryotherapy has been shown to alleviate symptoms of mucositis alleviating oral pain and inability to maintain nutritional status. In a randomised controlled trial we have shown that patients receiving oral cryotherapy had less mucositis, less use of i.v. opioides and fewer doses of total parenteral nutrition (TPN) than a control group receiving routine oral care. Adult patients scheduled for bone marrow transplantation were randomly assigned to experimental (EXP) or control (CTR) group. A stratified randomisation was used with regard to type of transplantation (autologous vs allogeneic/unrelated donor (URD)). Randomisation was performed between January 2002 and August 2004. The final sample consisted of 78 patients, (31 autologous BMT and 8 allogeneic/URD BMT), and 39 constituted the CTR group and received standard treatment (31 autologous BMT and allogeneic/URD BMT). Concern has been raised for a possible protection of tumor cells by cryotherapy which could increase the risk of relapse and reduce survival. Thee aim of the present study was to investigate any difference in survival and relapse rates 5 years post-BMT for the two treatment groups from the randomised study. After 5 years, 25/39 (64%) of the cryotherapy patients were alive compare to 15/39 (38%) of the control group (odds ratio 0,35, 95 % CI 0,14–0,88, p = 0,025)(Figure 1). No significant difference could be found with regard to the relapse rate between the groups. Most of the deaths were due to relapse. The study offers no support for the speculation about tumor protection from cryotherapy during high dose chemotherapy conditioning for stem cell transplantation. These data indicate that oral cryotherapy is a safe prophylactic treatment for mucositis during chemotherapy. Unexpectedly, the cryotherapy group showed a significantly better 5-year survival. Further analyses are needed to explore the difference in survival rate. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts

Blood ◽  
2017 ◽  
Vol 129 (12) ◽  
pp. 1718-1728 ◽  
Author(s):  
David Hongo ◽  
Xiaobin Tang ◽  
Xiangyue Zhang ◽  
Edgar G. Engleman ◽  
Samuel Strober
Keyword(s):  
Bone Marrow ◽  
Dendritic Cells ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Nkt Cells ◽  
Cell Interaction ◽  
Nkt Cell ◽  
Total Lymphoid Irradiation ◽  
Key Points

Key Points Tolerance after bone marrow transplantation requires CD8+ DCs and NKT-cell interaction. CD8+ DCs and NKT cells become tolerogenic after conditioning with total lymphoid irradiation.

Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation

Blood ◽  
1990 ◽  
Vol 76 (1) ◽  
pp. 245-253 ◽  
Author(s):  
J Nemunaitis ◽  
JW Singer ◽  
CD Buckner ◽  
D Durnam ◽  
C Epstein ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Graft Failure ◽  
Myelogenous Leukemia ◽  
Control Group ◽  
Colony Stimulating Factor ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor

Abstract The effect of recombinant human granulocyte-macrophage colony- stimulating factor (rhGM-CSF) was evaluated in 37 patients with marrow graft failure after allogeneic (n = 15), autologous (n = 21), or syngeneic (n = 1) bone marrow transplantation. rhGM-CSF was administered by 2-hour infusion at doses between 60 and 1,000 micrograms/m2/d for 14 or 21 days. At doses of less than 500 micrograms/m2, rhGM-CSF was well-tolerated and did not exacerbate graft- versus-host disease in allogeneic transplant recipients. No patient with myelogenous leukemia relapsed while receiving rhGM-CSF. Twenty-one patients reached an absolute neutrophil count (ANC) greater than or equal to 0.5 x 10(9)/L within 2 weeks of starting therapy while 16 did not. None of seven patients who received chemically purged autologous marrow grafts responded to rhGM-CSF. The survival rates of GM-CSF- treated patients were significantly better than those of a historical control group.

Influence of reticuloendothelial hyperfunction on bone marrow transplantation

1962 ◽  
Vol 203 (3) ◽  
pp. 404-408 ◽  
Author(s):  
W. R. Wooles ◽  
N. R. Di Luzio
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Phagocytic Activity ◽  
Marrow Transplantation ◽  
Removal Rate ◽  
Whole Body ◽  
Control Group ◽  
Significant Impairment ◽  
X Irradiation ◽  
High Degree

Reticuloendothelial (RE) hyperfunction was induced in C57/BL mice by the administration of trypsinized zymosan or glucan. The exposure of RE hyperfunctional mice to 800 r whole-body X-irradiation produced no change in phagocytic activity as denoted by the intravascular removal rate of colloidal carbon. The saline-injected control group showed a significant impairment in RE phagocytic activity. Reticuloendothelial hyperfunction existing at the time of bone marrow transplantation did not alter the high degree of recovery from radiation exposure afforded by isologous bone marrow transplantation. However, survival in RE hyperfunctional animals appeared to be correlated to the genetic diversity of the transplanted marrow since RE hyperactive animals receiving the homo- or heterografts manifested a 100% mortality as opposed to a 30-day survival of 90% and 25% in the respective saline-treated irradiated mice. These findings demonstrate that the early acceptance or rejection of the transplant is influenced by the functional state of the RES and the genetic variation of the transplant.

scholarly journals Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial [see comments]

Blood ◽  
1992 ◽  
Vol 79 (11) ◽  
pp. 2834-2840 ◽  
Author(s):  
M Attal ◽  
F Huguet ◽  
H Rubie ◽  
A Huynh ◽  
JP Charlet ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Randomized Trial ◽  
Continuous Infusion ◽  
Marrow Transplantation ◽  
Low Dose ◽  
Control Group ◽  
Heparin Group ◽  
Dose Heparin ◽  
Low Dose Heparin

Abstract Hepatic veno-occlusive disease (VOD) is a major regimen-related toxicity after bone marrow transplantation (BMT). Endothelial injury, leading to deposition of coagulation factors within the terminal hepatic venules, is believed to be the key event in the pathogenesis of VOD. To evaluate the benefit and the safety of a VOD prophylaxis with anticoagulants, we conducted a prospective randomized trial of continuous infusion of low-dose heparin among 161 patients under-going either allogeneic (n = 79) or autologous BMT (n = 81). Patients were randomized to receive (n = 81) or not receive (n = 80) prophylactic heparin 100 U/kg/d by continuous infusion from day -8 until day +30 post-BMT. Heparin was found to be highly effective in preventing VOD, which occurred in 11 of 80 patients (13.7%) in the control group versus 2 of 81 (2.5%) in the heparin group (P less than .01). Furthermore, none of the 39 patients in the heparin group developed VOD after allogeneic BMT, versus 7 of 38 (18.4%) in the control group (P less than .01). This prophylactic effect was achieved without added risk of bleeding. Indeed, the low-dose heparin we used did not prolong the partial thromboplastin time and did not increase the red blood cell and platelet requirements. It is therefore recommended that heparin prophylaxis be part of early mortality prevention programs after BMT.

Patterns of Outcome Following Recurrence After Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma

1999 ◽  
Vol 17 (1) ◽  
pp. 216-216 ◽  
Author(s):  
J. Apostolidis ◽  
J. M. Foran ◽  
P.W.M. Johnson ◽  
A. Norton ◽  
J. Amess ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Follicular Lymphoma ◽  
Marrow Transplantation ◽  
Autologous Bone Marrow Transplantation ◽  
B Cell Lymphoma ◽  
Autologous Bone Marrow ◽  
Control Group ◽  
Survival Pattern ◽  
Autologous Bone

PURPOSE: To assess the patterns of recurrence, management, and survival following recurrence after myeloablative therapy with autologous bone marrow transplantation (ABMT) in patients with follicular lymphoma (FL). PATIENTS AND METHODS: Between June 1985 and October 1995, 99 patients with FL received cyclophosphamide and total-body irradiation with ABMT as consolidation of second or subsequent remission. RESULTS: Median length of follow-up was 5½ years, and 33 patients developed recurrent lymphoma a median of 14 months after ABMT. In 26 patients, the recurrence was overt; in seven, it was detected on surveillance investigation. Twenty-six patients presented with recurrence at previous sites of disease. Twenty-two patients (67%) had FL at the time of recurrence; in 11 (33%), there was evidence of transformation to diffuse large B-cell lymphoma. Eight patients were managed expectantly; five were alive 21 to 53 months later. Twenty-five patients have required treatment to date; eight remained alive 6 months to 10 years later, and five were in remission. The Kaplan-Meier estimate of patients alive 5 years after recurrence is 45% (95% confidence interval, 27% to 62%). In univariate and multivariate analyses, survival after recurrence and overall survival after diagnosis were similar to those of a historical control group who received conventional treatment, before the introduction of myeloablative therapy (adjusted hazard ratio [HR], 1.56, P = .3, and HR, 1.34, P = .4, respectively). CONCLUSION: The survival pattern of patients with FL following recurrence after myeloablative therapy and ABMT suggests that this treatment does not compromise outcome in patients in whom it fails, reflecting the survival pattern of the disease when treated conventionally.

Sign in / Sign up

Export Citation Format

Share Document